Melanotan II benefits — what was actually demonstrated, and what was not

Melanotan II's claimed benefits — a tan without sun, appetite suppression, and increased sexual arousal — map onto its pharmacology accurately, which is why they are believable. The problem is that only one of them was ever measured in a controlled human study, and it was not the one people buy it for. The documented result is erections in men with psychogenic erectile dysfunction, from a ten-person crossover trial in 1998. The tanning effect that drives the entire market has no clinical trial behind it at all.

This is an unusual shape for an evidence base, and it is worth stating plainly: the best-supported effect of Melanotan II is one most buyers regard as a side effect, and the marketed effect is the unstudied one.

Wessells and colleagues ran a double-blind, placebo-controlled crossover study in ten men with erectile dysfunction of no known organic cause, using RigiScan monitoring to measure erections objectively over a six-hour window (J Urol 1998).

• Clinically evident erections developed in 8 of 10 men on Melanotan II.
• Mean duration of tip rigidity above 80% was 38.0 minutes versus 3.0 minutes on placebo (p=0.0045).
• The dose was 0.025 mg/kg.
• Transient nausea, yawning and stretching, and decreased appetite were more frequent on the peptide than placebo, though none required treatment.

It is a well-designed study and a real finding. It is also n=10, over six hours, in one clinic, nearly three decades ago. It establishes that a melanocortin agonist can initiate erections in men with psychogenic ED. It says nothing about repeated use, nothing about tanning, and nothing about safety beyond a single session — and its listed side effects are the same nausea and appetite suppression cosmetic users report, present from the beginning as dose-related pharmacology rather than an anomaly.

Searching the peer-reviewed literature for Melanotan II and tanning does not return efficacy studies. It returns dermatology case reports, and they describe harms rather than benefits: melanoma in situ associated with melanotan use (Ong and Bowling, Australas J Dermatol 2012) and multiple new atypical melanocytic naevi appearing after two injections (Reid et al., Ir Med J 2013).

Case reports cannot establish causation — that is their standard limitation and it applies here. But the asymmetry is informative by itself. For the use that accounts for essentially all consumption of this peptide, the published record consists of clinicians describing changed and malignant moles in users, with no counterweight of efficacy or safety trials, because none were run. If a photoprotective or cosmetic benefit is what someone is after, the compound with randomised trial data is the MC1-selective relative Melanotan I (afamelanotide), approved as an implant for a rare pain disorder.

Melanotan II is a synthetic cyclic analogue of alpha-melanocyte-stimulating hormone that activates melanocortin receptors non-selectively. The breadth is the explanation for the whole list of claimed benefits and the whole list of side effects at once:

• MC1R on melanocytes drives eumelanin synthesis — the tanning effect. The Vyleesi label states the relationship directly: MC1R activation leads to melanin expression and increased pigmentation (DailyMed).
• MC4R in hypothalamic circuits is associated with both appetite suppression and sexual arousal.
• Nausea, flushing and yawning travel with the same central activity, which is why they appeared in the 1998 trial at a therapeutic dose.

These effects cannot be separated by dose. A person taking Melanotan II for colour is also taking a hypothalamic melanocortin agonist, which is the reason its adverse-event list is longer than Melanotan I's rather than shorter.

The melanocortin line of research continued — with a different compound. Development moved to bremelanotide, a refined melanocortin agonist that completed full clinical trials and was approved by the FDA as Vyleesi, for acquired, generalized hypoactive sexual desire disorder in premenopausal women, and explicitly not for men, postmenopausal women, or performance enhancement (Vyleesi label). See PT-141 for that story.

That divergence is the clearest available statement about Melanotan II's status. The pharmacology was promising enough to pursue; the compound taken forward was a different, refined one. Melanotan II is the molecule development walked away from, and it is the abandoned molecule, not the approved successor, that is sold as a tanning agent.